Realtime | Geld | Brief | Zeit |
---|---|---|---|
6,100 | 6,300 | 26.07. | |
6,100 | 6,300 | 26.07. |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
11.06. | Cytek Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
06.06. | Cytek Biosciences Board Approves Share Repurchase Of Up To $50 Mln | 1 | RTTNews | ||
06.06. | Cytek Biosciences to effect an up to $50M share repurchase program | 1 | Seeking Alpha | ||
06.06. | Cytek Biosciences, Inc.: Cytek Biosciences Announces $50 Million Stock Repurchase Program | 1 | GlobeNewswire (USA) | ||
30.05. | Cytek Biosciences, Inc.: Cytek Biosciences to participate at the Goldman Sachs 45th Annual Global Healthcare Conference | 2 | GlobeNewswire (USA) | ||
28.05. | Cytek Biosciences, Inc.: 1-Laser and 2-Laser 6-Color TBNK Reagents from Cytek Biosciences Approved for Clinical Use in China | 144 | GlobeNewswire (Europe) | FREMONT, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Today Cytek Biosciences, Inc. (Nasdaq: CTKB) announced that its 1-laser and 2-laser 6-color TBNK reagent cocktails have received China National Medical... ► Artikel lesen | |
20.05. | Cytek Biosciences, Inc.: Cytek® Biosciences Adds Ability to Detect Subcellular Particles to Its Industry-Leading Cell Analysis Systems | 2 | GlobeNewswire (USA) | ||
13.05. | Earnings call: Cytek Biosciences outlines robust Q1 growth, eyes expansion | 1 | Investing.com | ||
13.05. | Cytek Biosciences, Inc. (NASDAQ:CTKB) Q1 2024 Earnings Call Transcript | 1 | Insider Monkey | ||
09.05. | Cytek Biosciences GAAP EPS of -$0.05, revenue of $44.9M | 1 | Seeking Alpha | ||
08.05. | Cytek Biosciences, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
08.05. | Cytek Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
08.05. | Cytek Biosciences, Inc.: Cytek Biosciences Reports First Quarter 2024 Financial Results | 116 | GlobeNewswire (Europe) | FREMONT, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results... ► Artikel lesen | |
30.04. | Cytek Biosciences, Inc.: Cytek® Biosciences to Spotlight Cell Analysis Solutions at Upcoming Conferences in the United States and Europe | 1 | GlobeNewswire (USA) | ||
29.04. | Cytek Biosciences, Inc.: Cytek Biosciences to Report First Quarter 2024 Financial Results on May 8, 2024 | 1 | GlobeNewswire (USA) | ||
19.03. | Cytek Biosciences CTO sells shares worth over $269k | 1 | Investing.com | ||
19.03. | Cytek Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
19.03. | Cytek Biosciences Names William McCombe To Succeed Patrik Jeanmonod As CFO; Reaffirms 2024 Outlook | - | RTTNews | ||
19.03. | Cytek appoints new CFO, reaffirms 2024 financial outlook | 1 | Investing.com | ||
19.03. | Cytek Biosciences appoints CFO | 1 | Seeking Alpha |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 79,10 | 0,00 % | BioNTech SE: BioNTech veröffentlicht am 5. August 2024 Ergebnisse für das zweite Quartal 2024 und informiert über operativen Fortschritt | MAINZ, Deutschland, 22. Juli 2024(Nasdaq: BNTX, "BioNTech" oder "das Unternehmen") wird am Montag, den 5. August 2024, die Ergebnisse für das zweite Quartal 2024 veröffentlichen. Darüber hinaus wird... ► Artikel lesen | |
MEDIGENE | 1,135 | -1,30 % | PTA-News: Medigene AG: Medigene präsentiert auf dem ESMO-Kongress 2024 | DJ PTA-News: Medigene AG: Medigene präsentiert auf dem ESMO-Kongress 2024
Unternehmensmitteilung für den Kapitalmarkt
Planegg/Martinsried (pta/23.07.2024/11:15) - Die Medigene AG ( http://www.medigene.de... ► Artikel lesen | |
CUREVAC | 3,402 | -1,10 % | CureVac: Anleger sollten nächste Woche insbesondere DARAUF achten! | CureVac-Aktionäre dürften derzeit in Hochstimmung sein. Schließlich findet sich der Kurs 11,66 Prozent höher wieder als vor einer Woche. An drei der fünf Sitzungen ging es für den Titel nach oben. Darunter... ► Artikel lesen | |
QIAGEN | 40,195 | +2,62 % | Biotech Report: Qiagen knapp im Plus, Evotec geben ab | (shareribs.com) Frankfurt / New York 23.07.2024 - Biotech-Aktien zeigen sich im deutschen Handel schwächer. Für Evotec und Biontech geht es abwärts, Qiagen kann sich behaupten. An der Wall Street verliert... ► Artikel lesen | |
AMGEN | 308,65 | +0,06 % | Amgen Aktie: Wachstumspotenzial trotz Herausforderungen | Die Amgen-Aktie hat in den letzten fünf Jahren eine beeindruckende Performance gezeigt und den Markt übertroffen. Mit einem Kursanstieg von 91% in diesem Zeitraum und einem Plus von 43% im vergangenen... ► Artikel lesen | |
NOVAVAX | 15,736 | -0,18 % | Market Whales and Their Recent Bets on NVAX Options | ||
BIOFRONTERA | 2,375 | +2,59 % | PTA-Adhoc: Biofrontera AG: Rechtsstreit um Import in die USA und daraus resultierende Prognose | DJ PTA-Adhoc: Biofrontera AG: Rechtsstreit um Import in die USA und daraus resultierende Prognose
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR
Leverkusen (pta/21.07.2024/14:45)... ► Artikel lesen | |
CRISPR THERAPEUTICS | 52,75 | -1,40 % | Is a Beat in the Cards for CRISPR Therapeutics (CRSP) in Q2 Earnings? | ||
REGENERON PHARMACEUTICALS | 997,00 | +2,15 % | Regeneron (REGN) to Report Q2 Earnings: What's in the Cards? | ||
ORGANOVO | 0,529 | -1,86 % | ORGANOVO HOLDINGS, INC. - 10-K/A, Annual Report | ||
INOVIO PHARMACEUTICALS | 10,280 | -1,34 % | INOVIO Pharmaceuticals, Inc.: Inovio Receives Advanced Therapy Medicinal Product Certificate from European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate INO-3107 | Data reviewed complies with standards that would be used to evaluate an EU Marketing Authorization Application
PLYMOUTH MEETING, Pa., July 25, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology... ► Artikel lesen | |
CLINUVEL | 9,045 | -0,44 % | Clinuvel Pharmaceuticals Limited: Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors | DÜSSELDORF, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing discussing its novel drug SCENESSE® (afamelanotide)... ► Artikel lesen | |
SANGAMO THERAPEUTICS | 0,825 | +4,02 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Reports on Pfizer's Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate | Giroctocogene fitelparvovec trial meets primary and key secondary objectives of superiority compared to prophylaxis
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today... ► Artikel lesen | |
INFLARX | 1,417 | +1,50 % | InflaRx N.V.: InflaRx's GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS) | JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today... ► Artikel lesen | |
INTELLIA THERAPEUTICS | 24,570 | +0,70 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen |